Pembroke Pines, FL (PRWEB) March 4, 2009
NextWave Research announces the publication of "Winning Companies in the Age of Personalized Medicine" highlighting several publicly-traded companies that should benefit from the integration of therapeutics and diagnostics such as CombiMatrix (Nasdaq:CBMX), Rosetta Genomics (Nasdaq:ROSG), VirtualScopics (Nasdaq:VSCP), Clarient (Nasdaq:CLRT), and OraSure Technologies (Nasdaq: OSUR).
Analyst John M. Putnam, CFA states that personalized medicine has been dominated by large companies developing and getting approved specific genetic tests such as Roche's AmpliChip, Monogram's Trofile, Bayer's Trugene and DAKO's Hercept.
However, he points out that "personalized medicine is now taking a much more varied path with more specialized companies playing a role. Some of these companies offer platform technologies upon which can be developed a family of diagnostic tests while others provide specialized diagnostic lab services upon which treatment decisions can be customized while still others are developing tests for personalized point of care testing."
In the article, Mr. Putnam discusses some of these specialized companies in the personalized medicine space including CombiMatrix (Nasdaq:CBMX), Rosetta Genomics (Nasdaq:ROSG), VirtualScopics (Nasdaq:VSCP), Clarient (Nasdaq:CLRT), and OraSure Technologies (Nasdaq: OSUR).
NextWave Research founder, Stephen M. Dunn states "The high costs of drugs today makes it imperative that targeted therapies are truly targeted to only those patients that will benefit. This is a critical area for significant future healthcare savings."
Interested readers can access the complete article and all of NextWave Research's analysis free-of-charge at http://www.NextWaveResearch.com with articles available in 11 languages.
About NextWave Research:
NextWave Research was created to address the dearth of professional Wall Street research coverage for quality small-cap companies. We believe that quality companies who choose to sponsor research analyst coverage provide a desperately needed service to both individual and institutional investors with reports and commentary freely available to all. We Don't Get Paid to Like Companies-We Get Paid by Companies We Like™.